How do you solve a problem like transfusion‐related acute lung injury?

Abstract

Background The last 20 years have seen substantial international efforts to minimize the incidence and risk of transfusion-related acute lung injury (TRALI). Nevertheless, TRALI remains a real morbidity and mortality risk to transfusion recipients. DiscussionThis review discusses the current knowledge on antibody-and nonantibody-mediated TRALI, as well as current and potential mitigation strategies.